Cellectricon is a leading provider of advanced cell-based screening services to accelerate drug discovery. Exploiting our Cellaxess® Elektra platform, our Discovery Services offering is ideal for compound profiling in excitable primary cells and native tissue. Our services help researchers identify phenotypic effects in highly relevant biological models early enough in a project’s lifecycle to add real value to the decision of whether to pursue or eliminate a compound, which translates to considerable cost savings in the drug development business.
For more information about Cellectricon please visit www.cellectricon.com.
